Clopidogrel (brand name Plavix) is an antiplatelet agent. Clopidogrel reduces the risk of myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS).
Results of genetic testing require careful interpretation. A number of factors are taken into account when determining whether clopidogrel is an appropriate treatment for an individual.
In general, if a person has one or two variant copies of the gene, then that person may have an altered response to clopidogrel.
The degree of responsiveness depends upon the variation(s) present and upon the person.
Not every laboratory will test for every gene variant. A less common gene variant may be present that is not detected by the test.